4.7 Review

Bruton's Tyrosine Kinase and Its Isoforms in Cancer

期刊

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.668996

关键词

cancer; BTK; PI3K; kinase inhibitor; metastasis

资金

  1. Research Foundation for the State University of New York [69344]
  2. Capital Region Medical Research Institute

向作者/读者索取更多资源

BTK is a soluble tyrosine kinase with important roles in B cells and epithelial cancers. Inhibition of BTK has been approved by the FDA for treating multiple malignancies, showing promising therapeutic potential.
Bruton's tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies. Targeting BTK with recently developed BTK inhibitors has been approved by the Food and Drug Administration (FDA) for the treatment of several hematological malignancies and has transformed the treatment of several B-cell malignancies. The roles that BTK plays in B cells have been appreciated for some time. Recent studies have established that BTK is expressed and plays pro-tumorigenic roles in several epithelial cancers. In this review, we focus on novel isoforms of the BTK protein expressed in epithelial cancers. We review recent work on the expression, function, and signaling of these isoforms and their value as potential therapeutic targets in epithelial tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据